跳至主要内容
临床试验/NL-OMON20689
NL-OMON20689招募中不适用

The role of glycosaminoglycans and macrophages in salt-sensitivity of blood pressure

Amsterdam UMC, location AMC0 个研究点目标入组 75 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • All subjects:
  • -Age between 18 and 40 years;
  • -Office BP = 140/90 mmHg;
  • -A body mass index = 30 kg/m2;
  • -Capable of giving written informed consent and able to comply with the requirements and restrictions listed in the informed consent form.
  • Microalbuminuric type 2 diabetes patients:
  • -Known with Diabetes Mellitus type 2;
  • -With microalbuminuria defined as: Either albuminuria 20-200 mg/L in a morning urine sample; or albuminuria 30-300 mg/24 hrs collected in a 24-hours urine collection; or albumin-to-creatinin ratio 2.5-25 mg/mmol in a morning urine sample
  • -Stable renal function (eGFR 45-90 ml/min/1.73m2) with or without on stable therapy with RAAS inhibiting agents
  • -HbA1c levels below 10.0% (86 mmol/mol) during the 6 months preceding the study
  • Nondiabetic CKD patients
  • -Known with CKD stage 2 – 3a;
  • -Stable renal function during the 6 months preceding the study (eGFR 45-90 ml/min/1.73m2) with or without on stable therapy with RAAS inhibiting agents;
  • -With albuminuria defined as: Either albuminuria >200 mg/L in a morning urine sample; or albuminuria 500 – 3000 mg/24 hrs collected in a 24-hours urine collection; or albumin-to-creatinin ratio >25 mg/mmol in a morning urine sample
  • Healthy volunteers:
  • -Healthy, as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination (PE) and laboratory tests carried out in the screening visit.

排除标准

  • -An office BP >140/90 mmHg;
  • -A body mass index >30 kg/m2;
  • -Use of systemic corticosteroids;
  • -Use of NSAIDs > 2 times a week;
  • -A major illness in the past 3 months of any significant chronic medical illness that the Investigator would deem unfavourable enrolment, including chronic inflammatory diseases, excluding the diseases of interest (DM2 and CKD) ;
  • -A history of any type of malignancy within the past 5 years with the expectation of successfully treated basal cell cancer of the skin;
  • -A history of any auto-immune disease ;
  • -A history of cardiovascular disease (in the past 6 months) defined as documented coronary artery disease including myocardial infarction, (un-)stable angina pectoris or acute coronary syndrome, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebrovascular disease including ischemic and haemorrhagic stroke or a subarachnodial bleeding, or peripheral artery disease including aortic aneurysmata;
  • -A history of eye surgery, glaucoma of retinal disorder;
  • -A history, within 3 years, of drug abuse (including benzodiazepines, opioids, amphetamine, cocaine, THC, methamphetamine);
  • -A history of alcoholism and/or drinking more than 3 units of alcohol per day. Alcoholism is defined as an average weekly intake of >21 units for males and >14 units for women. One unit is equivalent to 9 g of alcohol: a half-pint (~ 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 ml) measure of spirits;
  • -Smoking or use of tobacco products less than 30 days ago;
  • -Any other issue that in opinion of the Investigator could be harmful to the subject or compromise interpretation of the data.

研究者

发起方
Amsterdam UMC, location AMC

相似试验

The role of glycosaminoglycans and macrophages in... | 临床试验